In a sensitivity analysis, we found that if the biopsy compliance rate for the carrier cohorts was applied to the non-carrier control cohorts, an additional cancer might have been identified in the MSH2 and MSH6 non-carrier control cohorts. Here, MSH2 is linked to cancer.